APA (7th ed.) Citation

Keßler, T., & Müller-Tidow, C. (2019). Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML). Annals of hematology, 98(6), . https://doi.org/10.1007/s00277-019-03651-9

Chicago Style (17th ed.) Citation

Keßler, Torsten, and Carsten Müller-Tidow. "Phase II Clinical Trial of Pazopanib in Patients with Acute Myeloid Leukemia (AML), Relapsed or Refractory or at Initial Diagnosis Without an Intensive Treatment Option (PazoAML)." Annals of Hematology 98, no. 6 (2019). https://doi.org/10.1007/s00277-019-03651-9.

MLA (9th ed.) Citation

Keßler, Torsten, and Carsten Müller-Tidow. "Phase II Clinical Trial of Pazopanib in Patients with Acute Myeloid Leukemia (AML), Relapsed or Refractory or at Initial Diagnosis Without an Intensive Treatment Option (PazoAML)." Annals of Hematology, vol. 98, no. 6, 2019, https://doi.org/10.1007/s00277-019-03651-9.